John Arrowsmith

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

Paul Morgan, Piet H. van der Graaf, John Arrowsmith et al. · Drug Discovery Today · 2011 · 677 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents

John Arrowsmith, Simon F. Campbell, Peter E. Cross et al. · Journal of Medicinal Chemistry · 1986 · 211 citations

Pharmacy, Medicinal Chemistry, Pharmacology +6

UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells.

Michael Gwilt, John Arrowsmith, Kenneth J. Blackburn et al. · Journal of Pharmacology and Experimental Therapeutics · 1990 · 189 citations

Medicine, Cardiology, Pharmacology +17

Orphan drug development: an economically viable strategy for biopharma R&D

Kiran N. Meekings, Cory S.M. Williams, John Arrowsmith · Drug Discovery Today · 2012 · 158 citations

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +14

Selective class III antiarrhythmic agents. 1. Bis(arylalkyl)amines

Peter E. Cross, John Arrowsmith, Geoffrey N. Thomas et al. · Journal of Medicinal Chemistry · 1990 · 64 citations

Medicine, Medicinal Chemistry, Pharmacology +17